blinatumomab

Ligand id: 7384

Name: blinatumomab

References
1. Brischwein K, Parr L, Pflanz S, Volkland J, Lumsden J, Klinger M, Locher M, Hammond SA, Kiener P, Kufer P et al.. (2007)
Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class.
J. Immunother., 30 (8): 798-807. [PMID:18049331]
2. Dreier T, Lorenczewski G, Brandl C, Hoffmann P, Syring U, Hanakam F, Kufer P, Riethmuller G, Bargou R, Baeuerle PA. (2002)
Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody.
Int. J. Cancer, 100 (6): 690-7. [PMID:12209608]
3. Gökbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, Diedrich H, Topp MS, Brüggemann M, Horst HA et al.. (2018)
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.
Blood, 131 (14): 1522-1531. [PMID:29358182]
4. Kufer P, Lutterbuse R, Kohleisen B, Zeman S, Bauerle P. (2009)
Single chain antibody construct comprising binding domains specific for human CD3 and human CD19.
Patent number: US7635472. Assignee: Micromet Ag. Priority date: 31/05/2003. Publication date: 22/12/2009.
5. Mølhøj M, Crommer S, Brischwein K, Rau D, Sriskandarajah M, Hoffmann P, Kufer P, Hofmeister R, Baeuerle PA. (2007)
CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.
Mol. Immunol., 44 (8): 1935-43. [PMID:17083975]